Opportunity ID: 280511

General Information

Document Type: Grants Notice
Funding Opportunity Number: SOL-OAA-16-000026
Funding Opportunity Title: HIV Vaccine and Biomedical Prevention Research Project
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards: 2
Assistance Listings: 98.001 — USAID Foreign Assistance for Programs Overseas
Cost Sharing or Matching Requirement: Yes
Version: Synopsis 1
Posted Date: Dec 11, 2015
Last Updated Date:
Original Closing Date for Applications: Feb 02, 2016 All Application being submitted under this Notice of Funding Opportunity are due no later than 12:00(noon), EST, on February 2, 2016
Current Closing Date for Applications: Feb 02, 2016 All Application being submitted under this Notice of Funding Opportunity are due no later than 12:00(noon), EST, on February 2, 2016
Archive Date: Mar 03, 2016
Estimated Total Program Funding: $180,000,000
Award Ceiling: $160,000,000
Award Floor: $20,000,000

Eligibility

Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility”
Additional Information on Eligibility:

Additional Information

Agency Name: Agency for International Development
Description: The HIV/AIDS pandemic continues to be a major global health problem. Despite significantly accelerated implementation of effective prevention and treatment tools to address HIV and AIDS, over 2 million new infections occurred in 2014. Sub-Saharan Africa remains the region most severely affected, bearing the burden of 66% of the HIV positive people in the world. In sub-Saharan Africa, nearly half of the 25.8 million people living with HIV are women. Given the scope of the epidemic, new biomedical tools to prevent HIV are essential. The most promising of these is a safe and effective HIV vaccine that provides durable protection, thus providing a realistic and cost-effective means of reversing HIV on a population level. It is highly unlikely that a global, sustainable solution to the AIDS pandemic will be economically or logistically feasible in the absence of a safe and effective HIV vaccine.

Developing and delivering an AIDS vaccine for those most in need will represent a transformational scientific breakthrough and is in lock-step with USAID’s commitment to high-impact development through innovation. Parallel to this noble scientific endeavor supported by USAID since 2001 are concerted efforts to enhance human resources and infrastructure, while creating and nurturing an enabling policy environment and key partnerships in low- and lower middle-income countries that contribute to sustained capacity for science, research and health systems strengthening in the regions most affected by HIV/AIDS.

Link to Additional Information:
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

Lealie M. Perry

Email:leperry@usaid.gov

Version History

Version Modification Description Updated Date

Folder 280511 Full Announcement-1 -> soloaa16000026 cover letter hvbp notice of funding opportunity 121115.pdf

Folder 280511 Full Announcement-1 -> soloaa16000026 hvbp notice of funding opportunity 121115.pdf

Folder 280511 Full Announcement-1 -> attachment a2.pdf

Folder 280511 Full Announcement-1 -> attachment a1.pdf

Folder 280511 Other Supporting Documents-Amendment No 2 1 -> AFINAL Amendment No 2 to SOL-OAA-16-000026.pdf

Folder 280511 Other Supporting Documents-Amendment to Solicitation 1 -> AFINAL Amendment No 1 to SOL-OAA-16-000026.pdf

Packages

2025-07-09T20:05:52-05:00

Share This Post, Choose Your Platform!

About the Author: